L3VLUP
ProSign in

ABBV · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ABBVJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ABBV
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterABBVJNJ
Q3 202031 holders, $16.4bn30 holders, $26.2bn
Q4 202027 holders, $18.4bn32 holders, $26.6bn
Q1 202126 holders, $16.6bn31 holders, $25.3bn
Q2 202129 holders, $16.0bn37 holders, $25.6bn
Q3 202126 holders, $12.8bn40 holders, $24.1bn
Q4 202129 holders, $15.3bn33 holders, $25.2bn
Q1 202225 holders, $18.8bn35 holders, $28.2bn
Q2 202222 holders, $17.4bn33 holders, $26.9bn
Q3 202227 holders, $15.4bn36 holders, $25.4bn
Q4 202225 holders, $17.8bn35 holders, $27.6bn
Q1 202329 holders, $17.0bn42 holders, $24.5bn
Q2 202332 holders, $13.2bn38 holders, $25.0bn
Q3 202337 holders, $15.9bn37 holders, $18.9bn
Q4 202335 holders, $15.5bn31 holders, $19.0bn
Q1 202425 holders, $18.9bn32 holders, $19.7bn
Q2 202428 holders, $19.3bn35 holders, $20.4bn
Q3 202426 holders, $23.1bn28 holders, $22.3bn
Q4 202425 holders, $20.5bn37 holders, $20.4bn
Q1 202531 holders, $24.5bn32 holders, $20.5bn
Q2 202539 holders, $20.2bn31 holders, $18.4bn
Q3 202534 holders, $27.1bn32 holders, $23.7bn
Q4 202523 holders, $27.7bn29 holders, $27.8bn
Q1 202627 holders, $26.8bn34 holders, $35.6bn
Q2 202630 holders, $33.2bn33 holders, $39.1bn
ABBV

Abbvie Inc

Holders
39
Reported value
$20.2bn
Buyers
26
Sellers
12

Breadth +14 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
31
Reported value
$18.4bn
Buyers
15
Sellers
16

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 44 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ABBV (13)

Balyasny Asset Management LLC, Capital World Investors, Citadel Advisors LLC, Freestone Grove Partners LP, Harris Associates LP, Hudson Bay Capital Management LP, Jane Street Group LLC, Moore Capital Management LP, PDT Partners LLC, Squarepoint Ops LLC, Tudor Investment Corp, Voloridge Investment Management LLC, Walleye Capital LLC

Only JNJ (5)

Eisler Capital Management Ltd, Markel Group Inc, Point72 Asset Management LP, Two Sigma Advisers LP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →